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ABSTRACT
Nonsense-mediated mRNA decay (NMD) is a eukary-
otic surveillance pathway that recognizes mRNAs
with premature stop codons and targets them for
rapid degradation. Evidence from previous studies
has converged on UPF1 as the central NMD fac-
tor. In human cells, the SMG1 kinase phosphory-
lates UPF1 at the N-terminal and C-terminal tails,
in turn allowing the recruitment of the NMD factors
SMG5, SMG6 and SMG7. To understand the molec-
ular mechanisms, we recapitulated these steps of
NMD in vitro using purified components. We find that
a short C-terminal segment of phosphorylated UPF1
containing the last two Ser-Gln motifs is recognized
by the heterodimer of SMG5 and SMG7 14–3–3-like
proteins. In contrast, the SMG6 14–3–3-like domain
is a monomer. The crystal structure indicates that the
phosphoserine binding site of the SMG6 14–3–3-like
domain is similar to that of SMG5 and can mediate
a weak phospho-dependent interaction with UPF1.
The dominant SMG6–UPF1 interaction is mediated
by a low-complexity region bordering the 14–3–3-like
domain of SMG6 and by the helicase domain and C-
terminal tail of UPF1. This interaction is phospho-
rylation independent. Our study demonstrates that
SMG5–SMG7 and SMG6 exhibit different and non-
overlapping modes of UPF1 recognition, thus point-
ing at distinguished roles in integrating the complex
NMD interaction network.
INTRODUCTION
The degradation of eukaryotic mRNAs is an important
mechanism in the regulation of gene expression. It allows
the cell to rapidly change protein expression levels in re-
sponse to intracellular or extracellular signals. In addi-
tion, mRNA decay pathways serve to maintain the fidelity
of gene expression by targeting aberrant transcripts that
would otherwise give rise to unphysiological and poten-
tially deleterious protein products [reviewed in (1,2)]. A
well-known example is nonsense-mediated mRNA decay
(NMD), which detects and degrades mRNA transcripts
containing a premature termination codon (PTC) [reviewed
in (3–6)]. PTCs arise from errors in transcription and RNA
processing, and from mutations in the genome. Addition-
ally, NMD also regulates the levels of diverse cellular mR-
NAs, accounting for ∼5–10% of the transcriptome [re-
viewed in (7)].
The NMD pathway was originally discovered in yeast (8)
and operates in all eukaryotes studied to date [reviewed in
(9,10)]. The prevailing model of NMD postulates that a ri-
bosome stalled at a PTC terminates translation in an aber-
rant manner due to adjacent cis-acting elements that are
not present in the context of normal termination, leading
to the assembly of trans-acting NMD factors that prompt
the degradation of the PTC-mRNA [reviewed in (6,11–14)].
The predominant and best-characterized cis-acting element
is the mammalian exon junction complex (EJC), a ribonu-
cleoprotein particle (RNP) that assembles on the open-
reading frame of spliced mRNAs (15). If present down-
stream of a PTC, the EJC acts in synergy with the stalled
ribosome to recruit NMD factors.
In humans, several NMD factors have been identified
to date (SMG1-SMG9, DHX34 and NAG/NBAS). Of
these, SMG1–SMG7 were first isolated in Caenorhabdi-
tis elegans and named after the original mutant pheno-
types (suppressor with morphogenic effect on genitalia)
(16–21). More recently, a genome-wide RNA interference
screen in C. elegans led to the identification of the two new
NMD genes, smgl-1 and smgl-2, that encode for the pro-
teins NAG/NBAS and DHX34 (22). Finally, the proteins
SMG8 and SMG9 were characterized in humans as regula-
tory co-factors of the protein kinase SMG1 (23). The core
of the NMD machinery comprises the three up-frameshift
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proteinsUPF1,UPF2 andUPF3 (corresponding to SMG2,
SMG3 and SMG4), which are conserved from yeast to hu-
mans (24–26). UPF1 is an RNAhelicase essential for NMD
(17,20,27,28). The catalytic activity of UPF1 is stimulated
upon formation of theUPF1–UPF2–UPF3 (UPF) complex
(29) and is thought to remodel the PTC-mRNA (30). In
mammals, the UPF complex also binds directly to the EJC
(29,31–33) and impacts on UPF1 phosphorylation (34).
The phosphorylation and dephosphorylation cycle of
UPF1 is essential for NMD in metazoans (18,35). UPF1
is phosphorylated by the phosphoinositide 3-kinase related
kinase SMG1 (18,21,36–39). SMG1 associates with two co-
factors, SMG8 and SMG9 (23,40) and with the ribosome
release factors eRF1 and eRF3 (34). In turn, phosphory-
lated UPF1 recruits SMG5, SMG6 and SMG7. These three
proteins share a phosphoserine-binding domain similar to
that found in 14–3–3 proteins (41). SMG5 and SMG7 form
a stable heterodimer that binds phosphorylated residues in
the C-terminus of UPF1 (38,42). SMG5 and SMG7 also
mediate UPF1 dephosphorylation (18,35) and target the
PTC-mRNA to sites of 5′–3′ RNA degradation known as
P bodies (43). SMG6 is not part of the SMG5–SMG7 com-
plex (35,43,44) and has distinct functional modules: it con-
tains two EJC-binding motifs or EBMs (45) and harbors
an endonuclease activity that cleaves the PTC-mRNA in
proximity of the ribosome (46–48). SMG6 has been shown
to bind the phosphorylated N-terminus of UPF1 in co-
immunoprecipitation (co-IP) assays (38), but contradictory
data from tethering assays have shown that the N-terminus
of UPF1 is dispensable (42).
Elucidating the macromolecular interactions between
phosphorylated UPF1 and the downstream SMG5–SMG7
and SMG6 factors is an important step toward understand-
ing the mechanisms that bring about NMD. We set out
to recapitulate the interactions in vitro using the available
knowledge from co-IP studies with endogenous proteins.
To this end, we reconstituted in vitro phosphorylated UPF1
and used it in biochemical assays. We show that SMG6 dif-
fers substantially from SMG5–SMG7 in the way it recog-
nizes UPF1. We solved the crystal structure of the SMG6
TPR domain and elucidate the structural basis for the dif-
ferences in the functions of SMG6 and SMG5–SMG7.
MATERIALS AND METHODS
Protein expression and purification
His- and His-GST tagged SMG6 TPR were expressed us-
ing Escherichia coli BL21-Gold (DE3) pLysS cells (Strata-
gene) grown in TB medium and induced overnight at 18◦C.
The cells were lysed in buffer A (20 mM Tris-HCl pH 7.5,
10 mM imidazole, 10% glycerol) supplemented with 200
mM NaCl and protease inhibitors (Roche). The proteins
were purified by Ni2+- affinity chromatography as an ini-
tial step and further purified over a HiTrap Q Sepharose
HP column (GE Healthcare) to remove minor contami-
nants. The His-tag was removed by treatment with Tobacco
Etch Virus (TEV) protease for crystallization studies. Size-
exclusion chromatography (SEC) on a Superdex 200 col-
umn (GE Healthcare) was performed as a final step of pu-
rification using buffer B (20 mM HEPES pH 7.5 and 2
mMDTT) supplemented with 100 mMNaCl and 2% glyc-
erol. Selenomethionine substituted protein was purified as
described above from E. coli grown in M9 media comple-
mented with the essential amino acids and selenomethion-
ine (49).
In order to purify the SMG5–7 TPR complex, His-
(TEV)-SMG7 and SMG5-His were co-expressed in E. coli
BL21 (DE3) STAR pRARE cells, which were grown and
induced as described above. The cells were lysed in buffer
A containing 250 mM NaCl. The proteins were purified
by Ni2+- affinity chromatography and subjected to treat-
ment with TEV protease overnight. A second Ni2+- affinity
column was performed to remove the excess SMG7 TPR,
which was further purified by SEC. Anion-exchange chro-
matography (HiTrap Q HP Sepharose) yielded a stoichio-
metric SMG5–7 TPR complex. The complex was stored in
buffer B supplemented with 300 mM NaCl and 10% glyc-
erol.
GST-UPF1 constructs were expressed in E. coli BL21
(DE3) STAR pRARE cells as described above. The cells
were lysed in buffer A supplemented with 500 mM NaCl,
0.1% NP-40 detergent and protease inhibitors and addi-
tionally with 1 M ZnCl2 and 1 mMMgCl2 for constructs
encompassing the CH and helicase domains. The proteins
were purified by sequential Ni2+- affinity and ion-exchange
chromatography (HiTrap Q/Heparin HP, depending on the
pI of the construct) and a final step of SEC, using a S200
column in buffer B containing 150 mMNaCl and 10% glyc-
erol. All UPF1 mutants were engineered using the Strata-
gene Quikchange kit and verified by DNA sequencing.
The proteins SMG6fl, SMG1 wt and SMG1 KD were
designed to contain an N-terminal HA-Flag tag and were
transiently expressed and purified from mammalian cells
by Flag-affinity chromatography. HEK 293T cells were
cultured in Dulbecco’s modified Eagle medium contain-
ing 10% fetal bovine serum (Gibco), 2 mM L-glutamine,
1000 U/ml penicillin and 0.1 mg/ml streptomycin (Gibco)
and transfected with mammalian expression plasmids us-
ing polyethyleneimine ‘Max’ (Polysciences Inc.,Mw40000).
The transfected cells were incubated at 32◦C for 72 h. The
cells were then resuspended in lysis buffer (1.5× phosphate
buffered saline, 1 mM MgCl2, 1 mM CHAPS and 10%
glycerol) supplemented with 0.5 g/ml DNase I, 60 g/ml
RNase A and protease inhibitors and incubated for 15 min.
The lysate was centrifuged at 17,000 × g for 15 min at 4◦C.
The clarified cell lysate was incubated with anti-Flag M2
resin (Sigma) at 4◦C for an hour. After extensive washing
to remove non-specifically bound proteins, the Flag-tagged
protein of interested was eluted from the resin with 100 M
of 1× Flag peptide (Sigma) in the same buffer.
Crystallization and structure determination
Native crystals of SMG6 TPR were grown at 20˚C by
sitting-drop vapor diffusion from drops formed by equal
volumes of protein (at 2 mg/ml) and of crystalliza-
tion solution containing 50 mM MES pH 5.5, 200 mM
CH3COONH4 and 2.5% 2-Methyl-2,4-pentanediol (MPD).
Crystals were cryoprotected with a final concentration of
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derivatised crystals were grown in similar conditions at 4˚C
and cryo-protected as described above.
Native and single-wavelength anomalous dispersion
(SAD) data were collected at the PXII and PXIII beamlines
of the Swiss Light Source (SLS) (Villigen, Switzerland), re-
spectively. Data were processed with XDS (50) and scaled
using Aimless (51). Selenium sites were first located with
SHELXD (52), following which experimental phases were
calculated using the AutoSol pipeline in Phenix (53). Iter-
ative cycles of model building and refinement were carried
out with COOT (54) and Phenix and the final model was
validated using Molprobity (55).
In vitro kinase assays
Full-length GST-UPF1 (1 g) was incubated with catalytic
amounts of either SMG1 wt or SMG1 KD proteins in ki-
nase reaction buffer (25 mMMOPS pH 7.2, 5 mMMgCl2,
10 mM -glycerophosphate, 50 g/ml BSA) at 30˚C. The
phosphorylation reactions were initiated by the addition of
a radiolabeled ATP mix, consisting of 1 mM ATP and 0.2
Ci of  -32P ATP and allowed to proceed for 1 h. The reac-
tions were quenched by the addition of SDS sample buffer
and analyzed by sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) and autoradiography.
GST pull-down assays
Experiments were performed by mixing ∼2 g of GST-
tagged (bait) protein with equal amounts of untagged (prey)
protein. GST-reaction buffer (20 mM HEPES pH 7.5, 125
mM NaCl, 2% glycerol, 2 mM DTT) was added to a fi-
nal volume of 45 l. Wherever indicated, GST-UPF1 con-
structs were phosphorylated (as described above) prior to
the addition of the prey protein. The reactionmixtures were
incubated at room temperature for 45 min, following which
15 l of 50% (v/v) suspension of Glutathione–Sepharose
beads (GE Healthcare) was added to each reaction mix-
ture. The resultant mixture was supplemented with 200 l
of binding buffer (20 mM HEPES pH 7.5, 150 mM NaCl,
10% glycerol, 2 mM DTT, 0.1% NP-40) and incubated at
4◦C for 1 h. The beads were washed four times with 500 l
binding buffer. Bound proteins were eluted with 20 mM re-
duced glutathione, resolved by SDS-PAGE and visualized
by staining with Coomassie.
co-IP assays
For co-IP studies, HEK 293T cells (cultured as described
above) were co-transfected with plasmids of HA-SMG6
constructs and Flag-His-UPF1fl using polyethyleneimine.
The SMG6 constructs were also co-transfected with Flag-
ILF2 as a negative control. Transfected cells were incu-
bated at 32◦C and harvested 72 h later. Cell extracts were
prepared in 250 l NET-G buffer (50 mM Tris-HCl pH
8.0, 150 mM NaCl, 0.1% NP-40, 1 mM EDTA, 10% glyc-
erol); 12 l of anti-Flag M2 resin (Sigma) were added to
200 l of each co-transfected cell extract and incubated at
4◦C for 1 h. The beads were washed four times with 1 ml
NET-G buffer to remove non-specifically bound proteins,
while Flag-tagged proteins and their interaction partners
were eluted with 40 l of non-reducing SDS sample buffer.
The eluted proteins were resolved by SDS-PAGE and then
transferred onto polyvinylidene difluoride membranes for
analysis by western blotting. The membranes were probed
with mouse monoclonal anti-HA (Covance) and anti-Flag
(Sigma) antibodies to detect SMG6 and UPF1/ILF2, re-
spectively. A horseradish peroxidase-conjugated goat anti-
mouse antibody (Bio-Rad) used in combination with ECL
prime western blotting detection reagent (GE Healthcare)
enabled detection of the tagged proteins by chemilumines-
cence.
Analytical ultracentrifugation
Sedimentation velocity experiments were performed on an
Optima XL-I analytical ultracentrifuge (Beckman Inc.) us-
ing an An 60 Ti rotor and double-sector epon centerpieces.
The proteins were used in analytical ultracentrifugation
(AUC) buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 5%
glycerol) at 0.4 mg/ml. Buffer density and viscosity were
measured using a DMA 5000 densitometer and an AMVn
viscosimeter, respectively (both Anton Paar). Protein con-
centration distribution was monitored at 280 nm, at 50 000
rpm and 20◦C. Time-derivative analysis was computed us-
ing the SEDFIT software package, version 12.1b (56), re-
sulting in a c(s) distribution and an estimate for the molec-
ular weight Mf (from the sedimentation coefficient and the
diffusion coefficient, as inferred from the broadening of
the sedimentation boundary, assuming all observed species
share the same frictional coefficient f/f0).
RESULTS AND DISCUSSION
Human SMG5–SMG7 and SMG6 TPRs bind in vitro phos-
phorylated UPF1 with different efficiencies
UPF1 has a central helicase region with the catalytic AT-
Pase core (consisting of the RecA1, RecA2, 1B and 1C do-
mains) and the regulatory CH domain, which modulates
binding to UPF2 as well as to RNA (Figure 1A) (29,57,58).
In metazoans, the helicase region of UPF1 is flanked by
N- and C-terminal tails, which can be phosphorylated at
Ser-Gln (SQ) motifs by the SMG1 kinase (21,35,38). The
tails regulate the helicase activity of UPF1 (59) as well as
its interaction with SMG5, SMG6 and SMG7 (38,41,42).
Since phosphomimetic mutants of 14–3–3 targets often do
not completely reproduce the effects of phosphorylation
(60), we set out to obtain the 410 kDa human SMG1 ki-
nase in a recombinant form.We used transiently transfected
HEK 293T cells to express and purify SMG1 wild-type
(SMG1 wt, Figure 1B, left panel, lane 1) and, for control
experiments, a SMG1 mutant containing the D2331A sub-
stitution that renders the kinase catalytically inactive (21)
(SMG1 KD, Figure 1B, left panel, lane 2). Using a ra-
dioactive kinase assay, we demonstrate that SMG1 wt was
able to phosphorylate UPF1fl (Figure 1B, right panel, lane
1). The phosphorylation can be specifically attributed to
SMG1 since no background phosphorylation was observed
with the SMG1 KD mutant (Figure 1B, right panel, lane
2). Phosphopeptide analysis combined with LC-MS/MS
confirmed that UPF1 was phosphorylated by SMG1 at SQ
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Figure 1. Interaction of human SMG5, SMG6 and SMG7 with in vitro
phosphorylated UPF1. (A) Schematic representation of the domain or-
ganization of full-length (fl) human UPF1, SMG5, SMG6 and SMG7.
Folded domains are shown as rectangles and low-complexity sequences
as lines. In UPF1, the CH domain (in green) and the ATPase core do-
mains (RecA1 and 2, 1B and 1C, colored yellow, orange and red, respec-
tively) are indicated. The regions N- and C-terminal of the core contain
the SMG1 phosphorylation sites. The TPR domains of SMG5, SMG6
and SMG7 comprise the 14–3–3 and helical hairpins domain, which are
colored orange and teal, respectively. The SMG5 TPR domain is bifur-
cated by a long linker, which was deleted in the construct used in this study.
The N-terminal EBMs of SMG6 are shown as boxes. In brown are the ac-
tive and catalytically dead (d) PIN domains at the C-terminus of SMG6
and SMG5, respectively. (B) Left panel: SDS-PAGE analysis of catalyti-
cally active (wt) and inactive (kinase-dead, KD) SMG1 proteins purified
from HEK 293T cells. The asterisk (*) indicates a contaminant (methylo-
some) that co-purifies with SMG1. Right panel: in vitro kinase assay per-
formed using purified SMG1 proteins and UPF1fl as a substrate. A cor-
responding Coomassie-stained gel of the radioactive kinase assay (using
 -32P ATP) indicates the enzyme: substrate ratio employed in the assay.
(C) GST pull-down assays of GST-UPF1fl (treated with active SMG1 wt
or inactive SMG1 KD mutant) and SMG5–7 TPR, SMG7 TPR, SMG6
TPR and SMG6fl. GST-Mtr4 was used as a negative control in this and
all other GST pull-down experiments. One-fifth of the reaction mixture
was used as input. Inputs and the bound fractions (precipitates) were ana-
lyzed on 8% SDS-PAGE gels and are shown in the top and bottom panels,
respectively. The SMG5–7 TPR complex showed a significant affinity to-
ward phospho-UPF1fl while SMG6fl binds UPF1fl in a phosphorylation-
independent manner. The TPR domains of SMG6 and SMG7 exhibit only
a weak affinity toward UPF1fl.
C-terminal tails (Supplementary Figure S1A). The phos-
phorylation sites detected by our mass-spectrometric anal-
ysis include residues Thr28, Ser1078, Ser1096 and Ser1116,
which were previously identified as sites of SMG1 phospho-
rylation in vivo (21,38). Interestingly, the N- and C-terminal
tails of UPF1 in isolation (without the CH and helicase core
domains) are also effective substrates for SMG1 (Supple-
mentary Figure S1B).
In order to analyze the interactions of UPF1 with the
NMD factors SMG5, SMG6 and SMG7,we recombinantly
expressed and purified fragments of these proteins. The do-
main architecture of human SMG5, SMG6 and SMG7 can
be extrapolated from previous structural studies and from
sequence analyses (Figure 1A). In the case of SMG7 and
SMG5, the 14–3–3-like domain and the adjacent helical
hairpins domain form a single unit (41,42) that will be re-
ferred to as the tetratricopeptide (TPR) region. The bound-
aries of the TPR region of human SMG7 (residues 1–499)
are known from previous structural studies (41). Sequence
analysis suggests that the TPR region of human SMG5
contains an evolutionary divergent 220 amino-acid inser-
tion that is not present in the sequence and structure of the
C. elegans orthologue (42). We removed the predicted in-
sertion in human SMG5 to obtain a proteolytically-stable
protein (SMG5 1–803, 408–632, thereafter referred to as
SMG5 TPR). SMG5 TPR was mostly insoluble on its own
(data not shown) but was soluble when co-expressed with
SMG7 TPR. The resulting complex of the TPR domains
of SMG5 and SMG7 is referred to as SMG5–7 TPR in the
text. SMG6 is expected to contain a similar 14–3–3 domain
that is positioned in the middle of the polypeptide chain
(Figure 1A). Based on sequence analysis, we engineered a
soluble construct of SMG6 TPR that spans residues 580–
1166.
We performed pull-down assays with phosphorylated
and unphosphorylatedGST-taggedUPF1, which were gen-
erated by incubating UPF1 either with SMG1 wt or SMG1
KD (Figure 1C). Consistent with previous co-IP studies,
UPF1fl co-precipitated the SMG5–7 TPR complex only
when phosphorylated (Figure 1C, compare lanes 1 and 2)
(38,41,42). The SMG7 TPR in isolation showed only weak
binding to phospho-UPF1 in the pull-down assay (Figure
1C, lane 3, compare with lane 1). Likewise, we did not ob-
serve significant binding of SMG6 TPR to phospho-UPF1
above background (Figure 1C, lane 5). The in vitro pull-
down assays with recombinant proteins thus show that the
SMG5 and SMG7 TPR domains heterodimerize for effi-
cient binding to phosphorylated UPF1, recapitulating the
results from cell-based studies (35,38,42).
SMG5–SMG7 binds in vitro a phosphorylated stretch of
UPF1 containing the two C-terminal SQ motifs
The SMG5–7 TPR heterodimer contains two potential
phosphoserine binding sites, one within each 14–3–3-like
domain (Figure 1A) (35,38,41). Immunoprecipitation stud-
ies have converged on Ser1096 in the C-terminal tail of
UPF1 as the most important phospho site for binding to
SMG7. However, the region of UPF1 required to bind
SMG5 is still unknown. To address this, we designed a series
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or both the N-terminal and the C-terminal tail, the CH do-
main or the helicase core (Figure 2A, top panel). The con-
structs were expressed and purified as GST-fusion proteins
from E. coli, phosphorylated in vitro by SMG1 and subse-
quently used in GST pull-down assays (Figure 2A, bottom
panels). The helicase core lacking the N- and C-terminal
tails did not efficiently precipitate SMG5–7 TPR (Figure
2A, lane 3). Removal of the C-terminal tail (UPF1C) sub-
stantially decreased binding (Figure 2A, lane 5), while re-
moval of the N-terminal tail had a less drastic effect (Fig-
ure 2A, lane 9). The N-terminal tail in isolation (UPF1NT)
was unable to pull down SMG5–7 TPR (Figure 2A, lane 7).
Instead, the C-terminal tail (UPF1CT, residues 917–1118)
precipitated SMG5–7 TPRwith a similar efficiency as com-
pared to UPF1fl (Figure 2A, lane 11, compare with lane 1).
As expected, the interaction was dependent on phosphory-
lation (Figure 2A, compare lanes 11 and 12). We concluded
that the C-terminal tail of UPF1 contains the major deter-
minants for binding the SMG5–7 TPR heterodimer.
To narrow down which portion of the UPF1 C-terminal
tail is required for SMG5–7 TPR binding, we engineered a
series of GST-fusion UPF1CT deletion constructs lacking
specific SQ motifs (Figure 2B, top panel) and performed
GST pull-down assays as before (Figure 2B, bottom pan-
els). The constructs UPF1CT1 (residues 1052–1118) and
UPF1CT2 (residues 1070–1118) recapitulated the binding
of UPF1CT to SMG5–7 TPR (Figure 2B, lanes 3 and 5,
compare with lane 1). UPF1CT2 is a 50-residue segment
comprising five serines in SQ motifs: S1073, S1078, S1089,
S1096 and S1116 (Supplementary Figure S1A). Removal of
the last two SQ motifs in the UPF1CT3 construct (residues
1052–1085) impaired SMG5–7 TPR binding (Figure 2B,
lane 7). The UPF1CT4 construct (residues 1086–1118) in-
cluding only the last two SQ motifs was, instead, sufficient
to bind SMG5–7 TPR (Figure 2B, lane 9, see also Supple-
mentary Figure S1C). Interestingly, immunoprecipitation
studies had implicated S1078 and S1116 for SMG5–7 bind-
ing, albeit with a weaker contribution than S1096 (38). The
in vitro pull-down assays with recombinant proteins thus
indicate that the segment of UPF1 centered at the strong
S1096 site and at the weaker S1116 site are sufficient for
binding the SMG5–7 TPR.
SMG6 TPR is a monomeric 14–3–3-like domain
Proteins of the 14–3–3 family are known to function as
homo- or heterodimers (61). SMG5 and SMG7 form a het-
erodimer via the interaction of their 14–3–3 domains, but
neither associates with SMG6 in vivo (35,38,41–44). Con-
sistently, in vitro pull-down assays showed no interaction
of GST-SMG6 TPR with either the SMG5–7 TPR com-
plex or SMG7 TPR in isolation (Figure 3A, lanes 1 and
2). We reasoned that the SMG6 TPR might self-assemble
in a homodimer, precluding its interaction with other TPR
proteins. However, the GST-SMG6 TPR bait failed to in-
teract with the untagged SMG6 TPR (Figure 3A, lane 3).
To exclude that the GST tag might interfere with binding,
we determined the oligomeric state of untagged SMG6TPR
by SEC and analytical ultra-centrifugation (Figure 3B, left
and right panels, respectively). We found that SMG6 TPR
was a monomer in solution and had no propensity for self-
interaction.
To understand the basis for the monomeric nature of
SMG6TPR, we determined its structure.We obtained crys-
tals of human SMG6 TPR that diffracted to 2.1 A˚ resolu-
tion and used SAD to solve the structure. The final model
was refined to 2.1 A˚ resolution, with anRwork of 20.6%,Rfree
of 23.7% and good stereochemistry (data collection and re-
finement statistics in Table 1). The model includes residues
580–1159, with the exception of disordered loops at residues
711–715, 823–878 and 955–963. The overall structure of
SMG6 TPR is similar to that of SMG7 TPR and SMG5
TPR (Figure 3C). SMG6 TPR features the typical 14–3–3
like domain (-helices 1–9, colored orange). It also has
a C-terminal helical hairpins domain with seven -helices
(10–16, colored teal) that are stacked perpendicular to
the 14–3–3-like domain. The helical hairpins domain of hu-
man SMG6 superposes with a root-mean-square deviation
(r.m.s.d.) of 2.1 A˚ over 70% of the C atoms with respect to
the corresponding domain in human SMG7. Besides differ-
ences in the relative orientation of the -helices, the loops
connecting them are generally longer in human SMG6 as
compared to the helical hairpins domains of SMG7 and
SMG5 (Supplementary Figure S2). Additionally, the linker
between the 14–3–3-like and the helical hairpins domain
is longer in SMG6 than in SMG7 (68 residues in SMG6
as compared to 11 residues in SMG7). Fifty-five of the 68
residues of this linker in SMG6 are disordered, as indicated
by dotted lines in the structure (Figure 3C and Supplemen-
tary Figure S2). The 14–3–3 like domains of SMG6 and
human SMG7 are instead more similar and can be super-
posed with an r.m.s.d. of 1.2 A˚ over 80% of their C atoms.
Although the r.m.s.d. of superposition between SMG6 and
SMG5 is considerably higher (2.7 A˚ over 65% of the C),
the helical architecture of the 14–3–3-like domain is com-
parable to that of SMG5 (Figure 3C).
We compared the heterodimerization surfaces of SMG5
and SMG7 with the same structural elements of SMG6.
The 14–3–3-like domains of C. elegans SMG5 and SMG7
interact with a major hotspot at their 4 helices, which ap-
proach closely particularly due to glycine residues that are
present at the equivalent position in the two proteins (Gly91
andGly80 inC. elegans SMG5 and SMG7, respectively and
Gly100 in human SMG7) (Figure 3D and Supplementary
Figure S3) (42). Mutation of these glycine residues to glu-
tamic acid has been shown to impair the SMG5–7 TPR in-
teraction (42). In the structure of human SMG6, an aspartic
acid (Asp683) is present at the equivalent position (Figure
3D and Supplementary Figure S3) and would be incompat-
ible with the dimerization observed in SMG5–7 TPR. In ad-
dition, the interaction interface in the C. elegans SMG5–7
TPR structure is characterized by several hydrophobic con-
tacts. One such contact involves a methionine residue in
the 2 helix of SMG7 (Met30). The equivalent residue in
SMG6 is a glutamate (Glu624) that would be incompati-
ble with an analogous hydrophobic environment (Supple-
mentary Figure S3). The structural analysis thus rational-
izes why SMG6 TPR does not form homo- or heterodimers
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Figure 2. The SMG5–7 TPR complex binds the extreme C-terminal segment of UPF1. (A) Top panel: schematic representation of the UPF1 constructs
designed to map the binding site of SMG5–7 TPR on UPF1. Bottom panel: GST pull-down assays of SMG5–7 TPR with the GST-UPF1 constructs
described in the top panel. The assays were carried out in the presence of either SMG1 wt or SMG1KDmutant as described for Figure 1C. The inputs and
precipitates were analyzed on 10%SDS-PAGEgels. In the presence of SMG1wt, the 200-residue stretch following theUPF1 helicase domain is sufficient for
binding SMG5–7 TPR (see also Supplementary Figure S1B). (B) Top panel: schematic representation of the GST-UPF1 C-terminal constructs designed
to map the SQ motifs that mediate binding of SMG5–7 TPR to UPF1. Bottom panel: GST pull-down assays (performed as described above) suggest
that residues S1096 and S1116, when phosphorylated, act as interaction motifs for SMG5–7 TPR (see also Supplementary Figure S1C). The inputs and
precipitates were analyzed on 15% SDS-PAGE gels. The asterisk (*) indicates a degradation product of GST-UPF1CT.
of the 14–3–3-like domain would result in steric and elec-
trostatic clashes in a putative dimer.
SMG6 binds UPF1 independently of phosphorylation
The 14–3–3-like domain of SMG6 has a similar arrange-
ment of residues at the phosphoserine binding site as com-
pared to SMG5 and SMG7. Many of the residues lining
this site are conserved among the three proteins (Figure 3E).
A detailed analysis indicates that the phosphoserine bind-
ing site in SMG6 is more similar to that of SMG5 than
SMG7. A conserved lysine residue at this site in SMG7 (Lys
66 in the human protein) is replaced by a conserved tyro-
sine in both SMG6 (Tyr649, human numbering) and SMG5
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Figure 3. Overall structure of the SMG6 TPR domain. (A) GST pull-down assays of GST-SMG6 TPR with that of other TPR domains, carried out as
in Figure 1C. The samples were analyzed on 10% SDS-PAGE gels; panels for inputs and precipitates are indicated. While the TPR domains of SMG5
and SMG7 interact to form a stable complex, that of SMG6 is unable to mediate such interactions. (B) Left panel: size-exclusion analyses of SMG5–7
TPR and SMG6 TPR proteins. The purified SMG5–7 TPR complex and SMG6 TPR were separately injected on a semi-analytical gel-filtration column
(Superdex 200 HR 10/30, GE Healthcare) and the chromatograms were overlaid. The size-exclusion analyses demonstrate that SMG6 TPR is a monomer
in solution (molecular weight of 68 kDa) in contrast to the dimeric SMG5–7 TPR (molecular weight of 123 kDa). Right panel: sedimentation velocity
AUC of SMG6 TPR. SMG6 TPR was monitored at 280 nm and 50 000 rpm at 20◦C for 16 h. The molecular weight of SMG6 was estimated from the
sedimentation coefficient and the diffusion coefficient. (C) Overall crystal structure of the TPR domains of SMG6 (left), human SMG7 (middle, PDB ID
1YAO) and C. elegans SMG5 (right, PDB ID 3ZHE). The structures are shown in the same orientation after optimal superposition of their N-terminal
14–3–3 domain. The helices within the N-terminal 14–3–3 domain (colored orange) encompass the phosphoserine-binding motif while the helices of the
C-terminal domain (colored teal) are arranged into helical hairpins. The highlighted region 1 depicts the hotspot of dimerization in the 14–3–3 domains, as
derived from the structure ofC. elegans SMG5–7 TPR. The highlighted region 2 indicates the phosphoserine-binding pocket within the 14–3–3 domains of
the three proteins. This and all other structure figures were generated using PyMOL (http://www.pymol.org). (D) A close-up view of the highlighted region
1 from Figure 3C. A conserved glycine residue in helix 4 of SMG7 and SMG5 (middle and right panels) is at the center of the SMG5–7 TPR interface.
The equivalent residue in helix 4 of SMG6 (left panel) is an asparate (D683, see also Supplementary Figure S3). (E) A close-up view of the highlighted
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Table 1. Data collection and refinement statistics
Data collection
Data set SAD Native
Beamline SLS PXIII SLS PXII
Space group P212121 P212121
Unit cell parameters (A˚) a = 61.6, b = 80.0, c = 124.1 a = 62.1, b = 80.7, c = 124.7
Wavelength (A˚) 0.98 0.99
Resolution Range (A˚) a 49.0–3.3 (3.5–3.3) 49.3–2.1 (2.2–2.1)
Unique reflections 9829 37 397
Multiplicity 38.7 6.4
Completeness (%) a 99.8 (98.9) 100.0 (99.8)
I/(I) a 21.2 (5.6) 13.8 (2.9)
Rsym (%)a 21.8 (85.5) 6.0 (57.3)
CC( 12 )





r.m.s.d. bond (A˚) 0.008
r.m.s.d. angle (o) 1.08





aParantheses indicate values in outermost shell.
bValues were calculated using the program Molprobity (55).
tary Figure S3). Thus, subtle differences in this pocketmight
modulate the binding of TPR proteins to phospho-UPF1.
Since SMG6 does not heterodimerize with SMG7, we asked
whether there might be an additional UPF1 binding site in
another part of SMG6. To this end, we expressed and pu-
rified SMG6fl from HEK 293T cells and performed GST
pull-down assays with in vitro phosphorylated (or mock-
phosphorylated) GST-UPF1fl (Figure 1C). In contrast to
SMG6 TPR in isolation, SMG6fl interacted with phospho-
rylated UPF1fl (Figure 1C, lane 7, compare with lane 5).
Unexpectedly, SMG6fl interacted with UPF1fl also in the
absence of phosphorylation (Figure 1C, lane 8).
In order to determine the domain of SMG6 that medi-
ates additional interactions with UPF1, we generated trun-
cation constructs of human SMG6 encompassing the N-
terminal domain (SMG6NT, residues 1–580), the TPR do-
main (SMG6TPR, residues 580–1166) or the TPR and PIN
domains together (SMG6CT, residues 580–1419) (Figure
4A). These constructs contained an N-terminal hemagglu-
tinin (HA) tag and were co-expressed in HEK 293T cells
together with Flag-UPF1fl or Flag-ILF2 (used as a nega-
tive control). We carried out co-IP assays with an anti-Flag
antibody (Figure 4B).With the caveat that only a small pro-
portion of the over-expressed UPF1 might be phosphory-
lated in these conditions, neither SMG6TPRnor SMG6CT
interacted with UPF1fl (Figure 4B, right panels, lanes 7
and 8). In contrast, SMG6NT recapitulated the binding of
SMG6fl to UPF1 (Figure 4B, right panels, lanes 5 and 6).
We concluded that the N-terminal region of SMG6 con-
tributes to its binding of UPF1.
The N-terminal region of SMG6 interacts with the helicase
domain and C-terminal tail of UPF1
We proceeded to narrow down the regions responsible for
the phosphorylation-independent interaction of SMG6 and
UPF1. The SMG6NT region is predicted to be largely un-
structured (Supplementary Figure S4) and cannot be ex-
pressed as a soluble protein in E. coli. The only func-
tion known at present for this region of SMG6 resides
in the EBM sequences that are present within the N-
terminal 160 residues. We designed two truncation con-
structs spanning non-overlapping segments of SMG6NT:
SMG6NT1 (residues 1–206), which contains both EBMs,
and SMG6NT2 (207–579) covering the low-complexity
stretch proximal to the TPR domain (Figure 4A). As be-
fore, we co-expressed these HA-tagged SMG6 constructs
with Flag-UPF1fl in HEK 293T cells and performed co-
IP assays with an anti-Flag antibody. We observed that
SMG6NT2 bound UPF1 in a manner similar to SMG6NT
(Figure 4C, lanes 4 and 6), while SMG6NT1 did not ex-
hibit significant binding toward UPF1 (Figure 4C, lane 5).
We concluded that the N-terminus of SMG6 interacts with
UPF1 via an unstructured stretch that is proximal to the
TPR domain and is distinct from the EJC-binding region
(SMG6NT2).
We next performed GST pull-down assays with different
GST-UPF1 constructs (Figure 2A) to identify the region
of UPF1 that mediates the interaction with the SMG6 N-
terminus. Since we could not purify SMG6NT2 in sufficient
quantity and purity, we used SMG6fl as a prey for the GST
pull-down assays (Figure 4D). We found that the binding
of UPF1fl to SMG6 was recapitulated only by UPF1N,
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Figure 4. The N-terminal domain of SMG6 encompasses multiple discrete protein–protein interaction motifs. (A) Schematic representation of the SMG6
constructs designed to map the binding site of UPF1 on SMG6. (B) co-IP assays of Flag-UPF1fl and the indicated HA-SMG6 constructs (SMG6fl,
SMG6NT, SMG6 TPR and SMG6CT). SMG6 constructs were co-transfected with UPF1 in HEK-293T cells. Cell lysates were subjected to IP using an
anti-Flag antibody. 2% of the total cell lysate of every sample was used as the input. Inputs and precipitates were analyzed by SDS-PAGE and immuno
blotting using the indicated antibodies and are depicted on the left and right panels, respectively. Flag-ILF2 was used as a negative control in this and
other co-IP experiments, which were carried out in the absence of RNase A. Only the N-terminal domain of SMG6 was precipitated by Flag-UPF1 in
a manner similar to SMG6fl, indicating the presence of a UPF1 interaction motif within this region. (C) Co-IP assays of Flag-UPF1fl and HA-tagged
SMG6 N-terminal constructs (SMG6NT, SMG6NT1 and SMG6NT2). The experiment was performed as described above. The phospho-independent
UPF1 interaction motif of SMG6 localized to a stretch that is proximal to the TPR domain and distinct from the EBMs located within the first 160
residues. (D) GST pull-down assays of different GST-UPF1 constructs (described in Figure 2A) and SMG6fl. The pull-downs and analysis were carried
out as described in Figure 1C. The inputs and precipitates are shown on the top and bottom panels, respectively. Both the CH-helicase core and the
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C-terminal tail (Figure 4D, lane 6, compare with lane 1). In
isolation, the UPF1 helicase region (UPF1hel) and the C-
terminal tail (UPF1CT) independently showed a weak in-
teraction with SMG6fl (Figure 4D, lanes 3 and 7). We con-
cluded that the binding region for the SMG6 N-terminus
maps to the helicase domain and C-terminal tail of UPF1.
However, unlike UPF2, binding of SMG6 to UPF1 did not
affect its catalytic (ATPase) activity (Supplementary Figure
S4B).
The UPF and EJC complexes can assemble with SMG6 and
SMG5–SMG7 with concurrent interactions
The contacts between UPF1 and SMG6 that we identi-
fied by in vitro pull-down assays and co-IP experiments
raised predictions and questions in the context of the known
NMD interaction network. It is well established that UPF1
uses the CH domain to bind UPF2 (62). UPF2 in turn
binds the N-terminal RRM domain of UPF3 to form the
ternary UPF complex (29,33,63). The observation that the
CH domain of UPF1 is not required for SMG6 binding
(Figure 4D, lane 4) indicates that UPF1 could bind UPF2–
UPF3 and SMG6 at the same time. In pull-down assays,
GST-UPF1fl could not only co-precipitate UPF2–UPF3
and SMG6 independently (Figure 5A, lanes 2 and 4), but
also together to form a SMG6–UPF1–UPF2–UPF3 com-
plex (Figure 5A, lane 6). Moreover, SMG6 uses different
segments in its N-terminal region to bind UPF1 and the
EJC, suggesting that these interactions could occur con-
comitantly. In pull-down assays, GST-UPF1fl indeed co-
precipitated the EJC in the presence of SMG6fl to form an
EJC–SMG6–UPF1 complex (Figure 5A, lane 5).
The UPF complex is known to bind the EJC via the C-
terminal region of UPF3 (29,31–33), forming the seven-
subunit EJC–UPF assembly (see also in the pull-down as-
say, Figure 5A, lane 3). The EBMs present in the C-terminal
tail of UPF3 and the EBMs in the N-terminal region of
SMG6 bind the EJC in a mutually exclusive manner, sug-
gesting that the recruitment of SMG6 and the UPF com-
plex to the EJC are separate steps in the NMD pathway
(45). However, from the EJC–SMG6–UPF1 and SMG6–
UPF1–UPF2–UPF3 interactions discussed above (Figure
5A, lanes 5 and 6), it is possible to envisage the forma-
tion of an EJC→SMG6→UPF1→UPF2→UPF3 complex
or of an EJC→UPF3→UPF2→UPF1→SMG6 complex
(where → represents a direct protein–protein interaction).
In these large complexes, either SMG6 or UPF3 would
bridge the interaction between the EJC andUPF complexes
(Figure 5C, right and left panels, respectively). Indeed,
GST-UPF1fl co-precipitated SMG6, UPF2, UPF3 and the
EJC proteins to form an EJC–SMG6–UPF1–UPF2–UPF3
complex (Figure 5A, lane 7). Assembly of the large com-
plex with the RRM domain of UPF3, which is capable of
binding UPF2–UPF1 but not recruiting the EJC, confirms
the role of SMG6 as a bridge between UPF1 and the EJC
(Supplementary Figure S5, lanes 3 and 7).
Finally, the finding that SMG6 binding to unphospho-
rylated UPF1 requires both the helicase domain and C-
terminal tail raises the question of whether this interac-
tion is mutually exclusive with the binding of SMG5–7
TPR to the phosphorylated C-terminal tail of UPF1. In the
presence of SMG1 wt, GST-UPF1fl co-precipitated both
SMG6fl and SMG5–7 TPR (Figure 5B, lane 3), suggesting
that UPF1 can, in principle, recruit SMG6 and SMG5–7
concomitantly.
CONCLUSIONS
Much like canonical 14–3–3 dimers, the dimeric nature of
SMG5–SMG7 is important for their function (35,42,44).
The in vitro data with recombinant proteins reported here
recapitulate the results from cell-based assays (38,42), con-
verging on the view that the 14–3–3-like domain of SMG7
contains a strong phosphoserine binding site that binds the
segment centered at phosphorylated Ser1096. In analogy
with 14–3–3 proteins (64), the motif that binds SMG7 is
the ‘gatekeeper’ whose presence is required for binding. The
14–3–3-like domain of SMG5, instead, contains a weaker
phosphoserine binding site that binds a segment centered
at Ser1116. The linker connecting Ser1096 and Ser1116 is
about the twice the length as compared to the minimal dis-
tance found in phosphorylated targets of canonical 14–3–
3 proteins (65). This observation fits with the finding that
the 14–3–3-like domains of SMG5 and SMG7 dimerize in
a back-to-back orientation that positions the two phospho-
serine binding sites at roughly twice the distance as com-
pared to canonical side-by-side 14–3–3 dimers (42).
In contrast to canonical 14–3–3 proteins, the SMG6TPR
is a monomer in solution. At the structural level, subtle
changes at the putative dimerization interface rationalize
the inability of SMG6 TPR to dimerize with either SMG5
or SMG7 TPRs. Subtle differences also exist at the phos-
phoserine binding site of SMG6, making it more similar to
the weaker site of SMG5 rather than to the stronger site in
SMG7. The dominant binding site for the interaction with
UPF1 resides in a region upstream of the 14–3–3-like do-
main of SMG6 and is thus provided within the same pro-
tein. In the case of SMG6binding, the ‘gatekeeper’ is a com-
posite site that binds the helicase core and the C-terminal
tail. Notably, this interaction between UPF1 and SMG6 is
phosphorylation independent. In light of reports that phos-
phorylated Thr28 in UPF1 is important for binding SMG6
in cells (38), it is possible that this site provides a secondary,
low affinity interaction to the 14–3–3-like domain of SMG6
that could act in synergy with the dominant site.
The interaction data we obtained indicate that phospho-
rylated UPF1 binds SMG5–SMG7 and SMG6 directly and
simultaneously, and is part of a larger complex that include
UPF2, UPF3 and the EJC (Figure 5C). These concomitant
interactions are stable enough to withstand in vitro reconsti-
tutions, but are likely to occur in a transient fashion and in
a sequential manner during NMD. The results raise a new
mechanistic hypothesis on the spatial and temporal dimen-
sions of the NMD interaction network. For example, the
recruitment of SMG6 near the EJC might not necessarily
occur afterUPF3 dissociation (45). It is possible that SMG6
binding to UPF1 increases the effective local concentration
of its twoEBMs, allowing them to dissociate theUPF3 from
the EJC. Furthermore, SMG1 can phosphorylate UPF1
efficiently, although studies with C. elegans mutants have
shown that phosphorylation of UPF1 by SMG1 also re-
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Figure 5. Assembly of complexes ofmultipleNMD factors in the presence of SMG6. (A) GSTpull-down assays ofGST-UPF1fl and SMG6fl in the presence
of the NMD factors UPF2, UPF3 and the EJC. The pull-down was performed as described in Figure 1C. The inputs and precipitates were analyzed on
4–12% Bis-Tris gels (Invitrogen) and are depicted in the top and bottom panels, respectively. SMG6fl simultaneously interacted with UPF1 (even in the
presence of UPF2 and UPF3) and the EJC, using its two distinct interaction motifs. The assembly of a large NMD complex consisting of SMG6, UPF1,
UPF2, UPF3 and EJC is shown in lane 7 (see also Supplementary Figure S5). (B) GST pull-down assays of GST-UPF1fl (treated with active SMG1 wt
or inactive SMG1 KD mutant) and SMG6fl and SMG5–7 TPR. The pull-downs and analysis were carried out as in Figure 1C. Top and bottom panels
depict inputs and precipitates, respectively. Upon phosphorylation, GST-UPF1 simultaneously interacted with SMG6fl and SMG5–7 TPR, indicating that
binding of the different TPR proteins to the C-terminus of UPF1 can occur concomitantly. (C) Model depicting the possible transient SMG6–UPF–EJC
complexes assembled in the course of NMD, recapitulating the results from this study and previous reports. UPF1 (colored yellow) is depicted as a bilobal
structure, with the small circle representing the N-terminal CH domain and the large circle representing the ATPase core. N-and C-terminal extensions of
UPF1 are shown as yellow lines and phosphorylation sites therein are depicted as red open circles. UPF2 (in light green) binds the CH domain of UPF1
and UPF3 (colored dark green), forming the UPF complex. The TPR domains of SMG5 and SMG7 (colored purple and magenta) bind the C-terminal
phospho sites of UPF1, while SMG6 TPR (colored orange) is thought to bind the N-terminal phospho site of UPF1. The N-terminus of SMG6 mediates
a strong interaction with UPF1 and is crucial for its recruitment to the UPF–EJC complex. The interaction between UPF1 and the EJC (colored blue) can
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UPF3 in the in vivo studies might simply reflect the step in
the pathway when phosphorylation takes place. Consistent
with these notions, it has been shown that SMG1 associates
with post-spliced mRNAs via UPF2 and via a subunit of
the EJC and that UPF2 dissociates SMG1 from its negative
regulators SMG8 and SMG9 (34,40). Thus, UPF1 might
be phosphorylated in the context of the EJC–UPF assem-
bly in vivo because the efficient recruitment of active SMG1
occurs in the context of this assembly.
The phosphorylation and dephosphorylation cycle of
UPF1 appears to be a relatively recent development in
evolution. In yeast, UPF1 lacks the unstructured SQ-
containing tails. However, a recentmass-spectrometry study
identified 11 novel phosphorylation sites in yeast Upf1p
(66). Furthermore, a putative ortholog of SMG7, Ebs1p,
was shown to function in the yeast NMD pathway possi-
bly by recruiting Upf1p to P-bodies (67,68). Our finding
that the helicase domain of human UPF1 binds SMG6 in a
phosphorylation-independentmanner raises yet another in-
teresting possibility that yeast Upf1p might use a similar in-
teraction mechanism to help recruiting another factor and
prompting RNA degradation. The expectation is that the
mechanisms of NMD in different species will eventually be
merged in a unified model, not only for the upstream steps
involving PTC-mRNA recognition but also for the down-
stream steps involving the targeting to degradation.
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